Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo.
Ehsan BahramiJan Philipp SchmidVindi JurinovicMartin BeckerAnna-Katharina WirthRomina LudwigSophie KreissigTania Vanessa Duque AngelDiana AmendKatharina HuntRupert ÖllingerRoland RadJoris Maximillian FrenzMaria SoloveyFrank ZiemannMatthias MannBinje VickChristian WichmannTobias HeroldAshok Kumar JayaveluIrmela JeremiasPublished in: Molecular cancer (2023)
These findings identify ADAM10 as an attractive therapeutic target for the future treatment of acute leukemias.